stockportfolio.pro
Stocks / ABUS vs TBPH
ABUS vs TBPH
Arbutus Biopharma Corporation and Theravance Biopharma, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arbutus Biopharma Corporation (ABUS) | Theravance Biopharma, Inc. (TBPH) | |
|---|---|---|
| Market cap | $0.8B | $0.8B |
| Revenue (latest FY) | $14.08M | $107.46M |
| Net income (latest FY) | $-33.50M | $105.89M |
| Revenue growth (5y CAGR) | 15.3% | 8.4% |
| Net margin | -237.9% | 98.5% |
| Return on equity | -43.7% | 35.7% |
| P/E ratio | 5.1 | 7.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ABUS — free Open TBPH — freeFrequently asked questions
Which is bigger, ABUS or TBPH?
Theravance Biopharma, Inc. is larger by market capitalization — $0.8B versus $0.8B.
Which grows faster, ABUS or TBPH?
Over the last five fiscal years, Arbutus Biopharma Corporation grew revenue faster — 15.3%/yr versus 8.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.